Appoints Dr. Darena Stoykova Zlateva as Chief Scientific Officer effective Nov 12, 2022

NIKA PHARMACEUTICALS, INC

Dr. Zlateva appointed CSO of Nika Pharmaceuticals effective Nov 12, 2022.
She holds a PhD in Immunology and a medical degree; prior roles at Sofia Medical Academy and European Medical Association.
Employment contract signed with Nika Europe Ltd., in which Nika owns a 40% stake.
CSO will manage research projects, represent company at scientific forums, and formulate long-term research strategy.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Dr. Darena Stoykova Zlateva

Chief Scientific Officer

NIKA · NIKA PHARMACEUTICALS, INC

Effective: 2022-11-12
Filed: November 15, 2022, 6:59 PM ET

On November 12, 2022, Nika Pharmaceuticals, Inc. (the “company”) appointed Dr. Darena Stoykova Zlateva as the company’s Chief Scientific Officer (“CSO”).

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Dr. Darena Stoykova Zlateva was appointed as Chief Scientific Officer at NIKA PHARMACEUTICALS, INC.

Action: appointed
Role: Chief Scientific Officer

Exact text from the filing

On November 12, 2022, Nika Pharmaceuticals, Inc. (the “company”) appointed Dr. Darena Stoykova Zlateva as the company’s Chief Scientific Officer (“CSO”).

View on SEC.gov

NIKA PHARMACEUTICALS, INC filing history →

Source: SEC EDGAR

accession 0001826466-22-000149

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.